Somewhat Favorable Media Coverage Somewhat Unlikely to Impact WAVE Life Sciences (WVE) Share Price

News coverage about WAVE Life Sciences (NASDAQ:WVE) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. WAVE Life Sciences earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.4196395642675 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

WAVE Life Sciences (WVE) opened at $39.35 on Monday. WAVE Life Sciences has a one year low of $15.15 and a one year high of $39.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.50 and a quick ratio of 11.50.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.03. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.77 million. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. research analysts predict that WAVE Life Sciences will post -3.76 earnings per share for the current fiscal year.

WVE has been the subject of a number of analyst reports. Mizuho set a $34.00 price target on WAVE Life Sciences and gave the stock a “buy” rating in a research report on Friday, August 18th. Jefferies Group restated a “buy” rating and issued a $40.00 price target (down previously from $42.00) on shares of WAVE Life Sciences in a research report on Thursday, August 10th. Zacks Investment Research upgraded WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 12th. BidaskClub upgraded WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Leerink Swann restated an “outperform” rating and issued a $53.00 price target (up previously from $42.00) on shares of WAVE Life Sciences in a research report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $41.60.

In related news, Director Ra Capital Management, Llc bought 423,398 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were acquired at an average price of $23.34 per share, with a total value of $9,882,109.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Chandra Vargeese sold 1,500 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $35.00, for a total value of $52,500.00. The disclosure for this sale can be found here. 53.00% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact WAVE Life Sciences (WVE) Share Price” was originally reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://weekherald.com/2017/12/04/wave-life-sciences-wve-getting-somewhat-positive-press-coverage-study-finds.html.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Insider Buying and Selling by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply